MedTrace Logo

A Study to Investigate the Next-day Residual Effects of TS-142 in Healthy Elderly Subjects

NCT05819710 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2025-02-28

No results posted yet for this study

Summary

This is a study to investigate the next-day residual effects of a single bedtime dosing of 5 mg and 10 mg of TS-142 in Japanese healthy elderly participants in double-blind manner.

Conditions

  • Healthy Subjects

Interventions

DRUG

TS-142

Single dose of 5 mg of TS-142

DRUG

TS-142

Single-dose of 10 mg of TS-142

DRUG

Zopiclone

Single-dose of 7.5 mg of zopiclone

DRUG

Placebo

Single-dose of placebo

Sponsors & Collaborators

  • Taisho Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Taisho Director · Taisho Pharmaceutical Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-15
Primary Completion
2023-08-25
Completion
2023-08-25

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05819710 on ClinicalTrials.gov